医学
肝损伤
胆汁淤积
冠状病毒
肝病
病因学
疾病
病理生理学
2019年冠状病毒病(COVID-19)
病态的
重症监护医学
内科学
传染病(医学专业)
出处
期刊:Journal of clinical and translational hepatology
[Xia & He Publishing]
日期:2020-03-28
卷期号:8 (1): 1-5
被引量:235
标识
DOI:10.14218/jcth.2020.00019
摘要
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (2019 coronavirus disease, COVID-19) since December 2019, from Wuhan, China, has been posing a significant threat to global human health. The clinical features and outcomes of Chinese patients with COVID-19 have been widely reported. Increasing evidence has witnessed the frequent incident liver injury in COVID-19 patients, and it is often manifested as transient elevation of serum aminotransferases; however, the patients seldom have liver failure and obvious intrahepatic cholestasis, unless pre-existing advanced liver disease was present. The underlying mechanisms of liver injury in cases of COVID-19 might include psychological stress, systemic inflammation response, drug toxicity, and progression of pre-existing liver diseases. However, there is insufficient evidence for SARS-CoV-2 infected hepatocytes or virus-related liver injury in COVID-19 at present. The clinical, pathological and laboratory characteristics as well as underlying pathophysiology and etiology of liver injury in COVID-19 remain largely unclear. In this review, we highlight these important issues based on the recent developments in the field, for optimizing the management and treatment of liver injury in Chinese patients with COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI